Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
RESEARCH TOOLSreports
Holding BLTE?
Track your performance easily
BLTE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$31.01 - $86.53
Previous Close$82.53
Volume81.04K
Average Volume (3M)60.32K
Market Cap
$2.54B
Enterprise Value$2.46B
Total Cash (Recent Filing)$88.16M
Total Debt (Recent Filing)$886.00K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Mar 28, 2025EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding29,149,444
10 Day Avg. Volume105,150
30 Day Avg. Volume60,319
Standard Deviation0.28
R-Squared0.08
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)26.62
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$105.00Price Target Upside27.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Belite Bio, Inc. ADR News
PremiumCompany Announcements
Belite Bio Advances in Retinal Disease Trials
PremiumCompany Announcements
Belite Bio Advances in Tinlarebant Trials, Appoints New CMO
PremiumPre-Earnings
Is BLTE a Buy, Before Earnings?
PremiumCompany Announcements
Belite Bio Offers New Warrant Opportunities to InvestorsOwnership Overview
7.30%
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
92.59% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $31.00 and its highest was $86.53 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Currently, no data Available
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is Mar 28, 2025 which is in 126 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on Nov 12, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.008.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -$0.33.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 30,612,358 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 3.192%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Among the largest hedge funds holding Belite Bio, Inc. ADR’s share is EntryPoint Capital, LLC. It holds Belite Bio, Inc. ADR’s shares valued at N/A.
---
Belite Bio, Inc. ADR Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$105.00 (27.35% Upside)
$105.00 (27.35% Upside)
Blogger Sentiment
Bullish
BLTE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 781.0 Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.93%
12-Months-Change
Fundamentals
Return on Equity
-40.04%
Trailing 12-Months
Asset Growth
101.09%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
---
BLTE Company Deck
---
BLTE Earnings Call
Q3 2024
0:00 / 0:00
---
BLTE Stock 12 Month Forecast
Average Price Target
$105.00
▲(27.35% Upside)
Technical Analysis
Best Analysts Covering BLTE
1 Year
1 Year Success Rate
15/16 ratings generated profit
1 Year Average Return
+67.27%
reiterated a buy rating 9 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +67.27% per trade.
---